BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zocco MA, Garcovich M, Lupascu A, Di Stasio E, Roccarina D, Annicchiarico BE, Riccardi L, Ainora ME, Ponziani F, Caracciolo G. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound. J Hepatol. 2013;59:1014-1021. [PMID: 23811306 DOI: 10.1016/j.jhep.2013.06.011] [Cited by in Crossref: 51] [Cited by in F6Publishing: 45] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Mogensen MB, Hansen ML, Henriksen BM, Axelsen T, Vainer B, Osterlind K, Nielsen MB. Dynamic Contrast-Enhanced Ultrasound of Colorectal Liver Metastases as an Imaging Modality for Early Response Prediction to Chemotherapy. Diagnostics (Basel) 2017;7:E35. [PMID: 28604623 DOI: 10.3390/diagnostics7020035] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
2 Roccarina D, Garcovich M, Ainora ME, Riccardi L, Pompili M, Gasbarrini A, Zocco MA. Usefulness of contrast enhanced ultrasound in monitoring therapeutic response after hepatocellular carcinoma treatment. World J Hepatol 2015; 7(14): 1866-1874 [PMID: 26207168 DOI: 10.4254/wjh.v7.i14.1866] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
3 Sacco R, Mismas V, Romano A, Bertini M, Bertoni M, Federici G, Metrangolo S, Parisi G, Tumino E, Bresci G, Giacomelli L, Marceglia S, Bargellini I. Assessment of clinical and radiological response to sorafenib in hepatocellular carcinoma patients. World J Hepatol 2015; 7(1): 33-39 [PMID: 25624994 DOI: 10.4254/wjh.v7.i1.33] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Muñoz NM, Minhaj AA, Maldonado KL, Kingsley CV, Cortes AC, Taghavi H, Polak U, Mitchell JM, Ensor JE, Bankson JA, Rashid A, Avritscher R. Comparison of dynamic contrast-enhanced magnetic resonance imaging and contrast-enhanced ultrasound for evaluation of the effects of sorafenib in a rat model of hepatocellular carcinoma. Magnetic Resonance Imaging 2019;57:156-64. [DOI: 10.1016/j.mri.2018.11.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
5 Di Costanzo GG, de Stefano G, Tortora R, Farella N, Addario L, Lampasi F, Lanza AG, Cordone G, Imparato M, Caporaso N. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma. Future Oncology 2015;11:943-51. [DOI: 10.2217/fon.14.291] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
6 Marisi G, Cucchetti A, Ulivi P, Canale M, Cabibbo G, Solaini L, Foschi FG, De Matteis S, Ercolani G, Valgiusti M, Frassineti GL, Scartozzi M, Casadei Gardini A. Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? World J Gastroenterol 2018; 24(36): 4152-4163 [PMID: 30271080 DOI: 10.3748/wjg.v24.i36.4152] [Cited by in CrossRef: 72] [Cited by in F6Publishing: 63] [Article Influence: 18.0] [Reference Citation Analysis]
7 Höner Zu Siederdissen C, Potthoff A. [Sonographic diagnostics of liver tumors]. Internist (Berl) 2020;61:115-22. [PMID: 31925480 DOI: 10.1007/s00108-019-00728-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Ippolito D, Querques G, Okolicsanyi S, Franzesi CT, Strazzabosco M, Sironi S. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study. Eur J Radiol 2017;90:34-41. [PMID: 28583645 DOI: 10.1016/j.ejrad.2017.02.027] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
9 Malone CD, Mattrey RF, Fetzer DT. Contrast-Enhanced Ultrasound (CEUS) for the Diagnosis and Management of Hepatocellular Carcinoma: Current Status and Future Trends. Curr Hepatology Rep 2016;15:307-16. [DOI: 10.1007/s11901-016-0324-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
10 Sacco R. Assessment of radiologic response to targeted therapies in patients with hepatocellular carcinoma. Future Oncol. 2014;10:2073-2079. [PMID: 25396778 DOI: 10.2217/fon.14.92] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
11 Salvatore V, Gianstefani A, Negrini G, Allegretti G, Galassi M, Piscaglia F. Imaging Diagnosis of Hepatocellular Carcinoma: Recent Advances of Contrast-Enhanced Ultrasonography with SonoVue®. Liver Cancer 2016;5:55-66. [PMID: 29234627 DOI: 10.1159/000367748] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
12 von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H. First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation. Diagnostics (Basel) 2016;6:E44. [PMID: 27916795 DOI: 10.3390/diagnostics6040044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
13 Chai W, Xie L, Zhao Q, Cheng C, Tian G, Jiang T, Wu P. Ultrasound and Contrast-enhanced Ultrasound Findings after Percutaneous Irreversible Electroporation of Hepatic Malignant Tumors. Ultrasound Med Biol 2020;46:620-9. [PMID: 31924420 DOI: 10.1016/j.ultrasmedbio.2019.12.012] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Helbert A, Von Wronski M, Colevret D, Botteron C, Padilla F, Bettinger T, Tardy I, Hyvelin J. Ultrasound Molecular Imaging With BR55, a Predictive Tool of Antiangiogenic Treatment Efficacy in a Chemo-Induced Mammary Tumor Model. Invest Radiol 2020;55:657-65. [DOI: 10.1097/rli.0000000000000661] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
15 Eschbach RS, Clevert DA, Hirner-Eppeneder H, Ingrisch M, Moser M, Schuster J, Tadros D, Schneider M, Kazmierczak PM, Reiser M, Cyran CC. Contrast-Enhanced Ultrasound with VEGFR2-Targeted Microbubbles for Monitoring Regorafenib Therapy Effects in Experimental Colorectal Adenocarcinomas in Rats with DCE-MRI and Immunohistochemical Validation. PLoS One 2017;12:e0169323. [PMID: 28060884 DOI: 10.1371/journal.pone.0169323] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
16 Wang H, Hristov D, Qin J, Tian L, Willmann JK. Three-dimensional Dynamic Contrast-enhanced US Imaging for Early Antiangiogenic Treatment Assessment in a Mouse Colon Cancer Model. Radiology 2015;277:424-34. [PMID: 26020439 DOI: 10.1148/radiol.2015142824] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
17 Battaglia V, Cervelli R. Liver investigations: Updating on US technique and contrast-enhanced ultrasound (CEUS). Eur J Radiol. 2017;96:65-73. [PMID: 29103478 DOI: 10.1016/j.ejrad.2017.08.029] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
18 Wang H, Lutz AM, Hristov D, Tian L, Willmann JK. Intra-Animal Comparison between Three-dimensional Molecularly Targeted US and Three-dimensional Dynamic Contrast-enhanced US for Early Antiangiogenic Treatment Assessment in Colon Cancer. Radiology 2017;282:443-52. [PMID: 27490690 DOI: 10.1148/radiol.2016160032] [Cited by in Crossref: 16] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
19 Cruz M, Ferreira AA, Papanikolaou N, Banerjee R, Alves FC. New boundaries of liver imaging: from morphology to function. Eur J Intern Med 2020;79:12-22. [PMID: 32571581 DOI: 10.1016/j.ejim.2020.06.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
20 Amadori M, Barone D, Scarpi E, Oboldi D, Amadori E, Bandi G, Rossi A, Ferroni F, Ragazzini A, Casadei Gardini A, Frassineti GL, Gavelli G, Passardi A. Dynamic contrast-enhanced ultrasonography (D-CEUS) for the early prediction of bevacizumab efficacy in patients with metastatic colorectal cancer. Eur Radiol 2018;28:2969-78. [PMID: 29417252 DOI: 10.1007/s00330-017-5254-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
21 Amin S, Bathe OF. Response biomarkers: re-envisioning the approach to tailoring drug therapy for cancer. BMC Cancer 2016;16:850. [PMID: 27814715 DOI: 10.1186/s12885-016-2886-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
22 Gao Y, Zheng DY, Cui Z, Ma Y, Liu YZ, Zhang W. Predictive value of quantitative contrast-enhanced ultrasound in hepatocellular carcinoma recurrence after ablation. World J Gastroenterol 2015; 21(36): 10418-10426 [PMID: 26420968 DOI: 10.3748/wjg.v21.i36.10418] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
23 Lo GM, Al Zahrani H, Jang HJ, Menezes R, Hudson J, Burns P, Mcnamara MG, Kandel S, Khalili K, Knox J, Rogalla P, Kim TK. Detection of Early Tumor Response to Axitinib in Advanced Hepatocellular Carcinoma by Dynamic Contrast Enhanced Ultrasound. Ultrasound in Medicine & Biology 2016;42:1303-11. [DOI: 10.1016/j.ultrasmedbio.2016.01.025] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
24 Liang Q, Kong L, Zhu X, Du Y, Tian J. Noninvasive Imaging for Assessment of the Efficacy of Therapeutic Agents for Hepatocellular Carcinoma. Mol Imaging Biol 2020;22:1455-68. [PMID: 31834570 DOI: 10.1007/s11307-019-01431-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Hyvelin JM, Gaud E, Costa M, Helbert A, Bussat P, Bettinger T, Frinking P. Characteristics and Echogenicity of Clinical Ultrasound Contrast Agents: An In Vitro and In Vivo Comparison Study. J Ultrasound Med. 2017;36:941-953. [PMID: 28240842 DOI: 10.7863/ultra.16.04059] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 4.6] [Reference Citation Analysis]
26 da Fonseca LG, Reig M, Bruix J. Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma. Clin Liver Dis 2020;24:719-37. [PMID: 33012455 DOI: 10.1016/j.cld.2020.07.012] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
27 Nam K, Stanczak M, Lyshchik A, Machado P, Kono Y, Forsberg F, Shaw CM, Eisenbrey JR. Evaluation of Hepatocellular Carcinoma Transarterial Chemoembolization using Quantitative Analysis of 2D and 3D Real-time Contrast Enhanced Ultrasound. Biomed Phys Eng Express 2018;4:035039. [PMID: 29887989 DOI: 10.1088/2057-1976/aabb14] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
28 Colagrande S, Calistri L, Campani C, Dragoni G, Lorini C, Nardi C, Castellani A, Marra F. CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib. Eur Radiol 2021;31:1608-19. [PMID: 32827266 DOI: 10.1007/s00330-020-07171-3] [Reference Citation Analysis]
29 Suzuki E, Ooka Y, Chiba T, Kobayashi K, Kanogawa N, Motoyama T, Saito T, Ogasawara S, Tawada A, Yokosuka O. Incidental tumor necrosis caused by the interventional alteration of hepatic arterial flow in patients with advanced hepatocellular carcinoma. Clin J Gastroenterol 2015;8:41-6. [PMID: 25481841 DOI: 10.1007/s12328-014-0542-y] [Reference Citation Analysis]
30 Delaney LJ, Tantawi M, Wessner CE, Machado P, Forsberg F, Lyshchik A, O'Kane P, Liu JB, Civan J, Tan A, Anton K, Shaw CM, Eisenbrey JR. Predicting Long-Term Hepatocellular Carcinoma Response to Transarterial Radioembolization Using Contrast-Enhanced Ultrasound: Initial Experiences. Ultrasound Med Biol 2021;47:2523-31. [PMID: 34130880 DOI: 10.1016/j.ultrasmedbio.2021.05.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Wang H, Hristov D, Qin J, Tian L, Willmann JK. Three-dimensional Dynamic Contrast-enhanced US Imaging for Early Antiangiogenic Treatment Assessment in a Mouse Colon Cancer Model. Radiology. 2015;277:424-434. [PMID: 26020439 DOI: 10.1148/radiol.2015142824]] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
32 Pang EHT, Chan A, Ho SG, Harris AC. Contrast-Enhanced Ultrasound of the Liver: Optimizing Technique and Clinical Applications. AJR Am J Roentgenol. 2018;210:320-332. [PMID: 29220210 DOI: 10.2214/ajr.17.17843] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
33 Taiji R, Nishiofuku H, Tanaka T, Minamiguchi K, Fukuoka Y, Saito N, Taguchi H, Matsumoto T, Marugami N, Hirai T, Kichikawa K. Useful Parameters in Dynamic Contrast-enhanced Ultrasonography for Identifying Early Response to Chemotherapy in a Rat Liver Tumor Model. J Clin Imaging Sci 2021;11:15. [PMID: 33767907 DOI: 10.25259/JCIS_6_2020] [Reference Citation Analysis]
34 Del Prete M, Di Sarno A, Modica R, Lassandro F, Giorgio A, Bianco A, Muto M, Gasperi M, Del Prete F, Colao A, Montesarchio V, Faggiano A; ENETS Centre of Excellence Multidisciplinary Group for Neuroendocrine Tumors in Naples (Italy). Role of contrast-enhanced ultrasound to define prognosis and predict response to biotherapy in pancreatic neuroendocrine tumors. J Endocrinol Invest 2017;40:1373-80. [DOI: 10.1007/s40618-017-0723-x] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
35 Hidaka H, Nakazawa T, Fujii S, Yanagihara M, Minamino T, Takada J, Tanaka Y, Okuwaki Y, Shibuya A, Koizumi W. Early evaluation of response to sorafenib for hepatocellular carcinoma by duplex Doppler ultrasonography. Hepatol Res 2015;45:976-85. [PMID: 25336196 DOI: 10.1111/hepr.12440] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
36 Wege H, Li J, Ittrich H. Treatment Lines in Hepatocellular Carcinoma. Visc Med 2019;35:266-72. [PMID: 31602390 DOI: 10.1159/000501749] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
37 McNamara MG, Le LW, Horgan AM, Aspinall A, Burak KW, Dhani N, Chen E, Sinaei M, Lo G, Kim TK, Rogalla P, Bathe OF, Knox JJ. A phase II trial of second-line axitinib following prior antiangiogenic therapy in advanced hepatocellular carcinoma. Cancer. 2015;121:1620-1627. [PMID: 25565269 DOI: 10.1002/cncr.29227] [Cited by in Crossref: 30] [Cited by in F6Publishing: 33] [Article Influence: 4.3] [Reference Citation Analysis]
38 Beckmann S, Simanowski JH. Update in Contrast-Enhanced Ultrasound. Visc Med 2020;36:476-86. [PMID: 33447604 DOI: 10.1159/000511352] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
39 Kim J, Kim JH, Yoon SH, Choi WS, Kim YJ, Han JK, Choi B. Feasibility of Using Volumetric Contrast-Enhanced Ultrasound with a 3-D Transducer to Evaluate Therapeutic Response after Targeted Therapy in Rabbit Hepatic VX2 Carcinoma. Ultrasound in Medicine & Biology 2015;41:3131-9. [DOI: 10.1016/j.ultrasmedbio.2015.07.031] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
40 Zhou J, Zhang H, Wang H, Lutz AM, El Kaffas A, Tian L, Hristov D, Willmann JK. Early prediction of tumor response to bevacizumab treatment in murine colon cancer models using three-dimensional dynamic contrast-enhanced ultrasound imaging. Angiogenesis 2017;20:547-55. [PMID: 28721500 DOI: 10.1007/s10456-017-9566-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
41 Ryu H, Kim JH, Lee S, Han JK. Therapeutic response monitoring after targeted therapy in an orthotopic rat model of hepatocellular carcinoma using contrast-enhanced ultrasound: Focusing on inter-scanner, and inter-operator reproducibility. PLoS One 2020;15:e0244304. [PMID: 33362203 DOI: 10.1371/journal.pone.0244304] [Reference Citation Analysis]
42 Bouattour M, Payancé A, Wassermann J. Evaluation of antiangiogenic efficacy in advanced hepatocellular carcinoma: Biomarkers and functional imaging. World J Hepatol 2015; 7(20): 2245-2263 [PMID: 26380650 DOI: 10.4254/wjh.v7.i20.2245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
43 Laterza L, Ainora ME, Garcovich M, Galasso L, Poscia A, Di Stasio E, Lupascu A, Riccardi L, Scaldaferri F, Armuzzi A, Rapaccini GL, Gasbarrini A, Pompili M, Zocco MA. Bowel contrast-enhanced ultrasound perfusion imaging in the evaluation of Crohn's disease patients undergoing anti-TNFα therapy. Dig Liver Dis 2021;53:729-37. [PMID: 32900648 DOI: 10.1016/j.dld.2020.08.005] [Reference Citation Analysis]
44 Han X, Dong J, Liu Z, Wu B, Tian Y, Tan H, Cheng W. Quantitative dynamic contrast-enhanced ultrasound to predict intrahepatic recurrence of hepatocellular carcinoma after radiofrequency ablation: a cohort study. International Journal of Hyperthermia 2020;37:1066-73. [DOI: 10.1080/02656736.2020.1817576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
45 Piscaglia F, Cucchetti A, Dietrich CF, Salvatore V. Towards new tools for refined management of patients with advanced hepatocellular carcinoma under systemic therapy: some enthusiasm with a word of caution. J Hepatol. 2013;59:924-925. [PMID: 23928406 DOI: 10.1016/j.jhep.2013.07.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
46 Kuzuya T, Ishigami M, Ishizu Y, Honda T, Hayashi K, Katano Y, Hirooka Y, Ishikawa T, Nakano I, Goto H. Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. PLoS One. 2015;10:e0138776. [PMID: 26421430 DOI: 10.1371/journal.pone.0138776] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
47 Zhan Y, Zhou F, Yu X, Luo F, Liu F, Liang P, Cheng Z, Han Z, Yu J. Quantitative dynamic contrast-enhanced ultrasound may help predict the outcome of hepatocellular carcinoma after microwave ablation. International Journal of Hyperthermia 2018;35:105-11. [DOI: 10.1080/02656736.2018.1483533] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
48 Chen Q, Tang L, Liu N, Han F, Guo L, Guo S, Wang J, Liu H, Ye Y, Zhang L, Liu L, Wang P, Li Y, He Q, Yang X, Tang Q, Li Y, Liang Y, Sun X, Xie C, Mo Y, Guo Y, Sun R, Mo H, Cao K, Guo X, Zeng M, Mai H, Ma J. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open-label, dose-escalation Study. Cancer Commun (Lond) 2018;38:66. [PMID: 30382933 DOI: 10.1186/s40880-018-0330-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
49 Lassau N, Bonastre J, Kind M, Vilgrain V, Lacroix J, Cuinet M, Taieb S, Aziza R, Sarran A, Labbe-Devilliers C, Gallix B, Lucidarme O, Ptak Y, Rocher L, Caquot LM, Chagnon S, Marion D, Luciani A, Feutray S, Uzan-Augui J, Coiffier B, Benastou B, Koscielny S. Validation of dynamic contrast-enhanced ultrasound in predicting outcomes of antiangiogenic therapy for solid tumors: the French multicenter support for innovative and expensive techniques study. Invest Radiol. 2014;49:794-800. [PMID: 24991866 DOI: 10.1097/rli.0000000000000085] [Cited by in Crossref: 76] [Cited by in F6Publishing: 32] [Article Influence: 10.9] [Reference Citation Analysis]